Geisinger Health System

SALT LAKE CITY — Myriad Genetics Inc., a molecular diagnostic company committed to producing tests to assess patient risk based in Salt Lake City, has reported that a new diagnostic test found 51 percent more patients with a higher risk of hereditary breast and ovarian cancer than did testing for BRCA1 and BRCA2 genes alone.